JAZZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Jazz Pharmaceuticals (JAZZ) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong growth potential driven by its oncology pipeline, positive financial performance, and consistent analyst support. Despite minor insider selling and neutral hedge fund activity, the company's fundamentals and growth outlook outweigh these concerns.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram of 1.261, and a neutral RSI of 51.473. The current pre-market price of $182.72 is near the pivot level of $183.671, suggesting a stable entry point. Key resistance levels are at $194.917 and $201.865, while support levels are at $172.425 and $165.477.
Analysts have consistently raised price targets, with a range of $220-$275, indicating strong confidence in the company's growth prospects.
The oncology pipeline, particularly Ziihera, is expected to drive significant revenue growth.
Q4 financials showed YoY revenue growth of 10.09% and net income growth of 6.45%.
Zymeworks' $250M royalty-backed financing agreement for Ziihera enhances financial flexibility and supports future growth.
Insider selling has increased by 1504.67% over the last month, which may indicate reduced confidence from company insiders.
Hedge funds remain neutral with no significant trading trends, showing limited institutional enthusiasm.
Gross margin dropped slightly by -0.76% YoY in Q4 2025.
In Q4 2025, Jazz Pharmaceuticals reported a revenue increase of 10.09% YoY to $1.197B, net income growth of 6.45% YoY to $203.45M, and EPS growth of 7.07% YoY to $3.33. However, gross margin slightly declined to 73.01%, down -0.76% YoY.
Analysts are overwhelmingly positive on JAZZ, with multiple firms maintaining Buy or Overweight ratings. Recent price target increases range from $220 to $275, reflecting confidence in the company's oncology pipeline and financial performance. Barclays highlights the 'sticky' CNS base business and oncology-fueled growth, while BofA and Wells Fargo emphasize the potential of Ziihera in gastroesophageal adenocarcinoma.
